Canada Markets open in 3 hrs 22 mins

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
53.92-3.16 (-5.54%)
At close: 04:00PM EDT
53.92 0.00 (0.00%)
Pre-Market: 05:27AM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • c
    The market is about to get crushed...Are you prepared? do this now. Check out
  • M
    I am staying far away from NTLA- It looks like it is going to drop off a cliff. I actually get way better stocks at
  • D
    NTLA and BITCOIN on the rise 🚀
  • s
    I highly recommend to any day traders out there! The daily email watchlists are top-notch!
  • E
    Congrats on the HAE data. Pretty impressive.
  • i
    $BEAM conversation
    The market is a fickle mistress. Intellia announces new promising results and all things CRISPR falls in unison. $NTLA $EDIT $BEAM $VERV
  • M
    Intellia understands CRISPR and is confidently executing well on all programs. Less than a week away until clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) is made public. I’m excited 😜
  • B
    A short quiz coming very soon. This will be positive by end of the day. This is very big news and this company is now takeover target. Buy with both hands.
  • J
    Wow, risky gene therapy for HAE from NTLA turns out to be less effective than safe oral treatment Orladeyo which boasts over 94% attack-free days.
  • E
    JP Morgan initiates coverage with an Overweight and $81.00 PT. Adds NTLA to focus list as stock with ‘growth’ potential.
  • E
    JMP Securities raises NTLA price target to $111.00 and assigns overweight status.
  • t
    The market could be about to tank...Do this now.For more info
  • C
    September 16, 2022 7:00 AM EDT
    Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
    Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases
    A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively, at week eight
    HAE attacks were reduced by 91% in the 25 mg dose cohort through week 16; two of three patients remain attack free since treatment with third patient attack free since week 10 through latest follow-up
    NTLA-2002 was generally well-tolerated at both dose levels
    Intellia plans to initiate the Phase 2 dose-expansion portion of the study in 1H 2023
    Intellia to host investor event today, Friday, September 16 , at 8:00 a.m. ET
  • R
    Took care of 6 of them in my career- how the disease evolved from Danazol (cheaper, less effective with side effects) to infusions for frequent episodes and abortive medications (effective, expensive and life long treatments) - now to a real cure.
    Most of these patients are in cohorts - when you inform a patient about Intellia- who provide their toll free number, also ask your patient to share with their family members.
  • J
    Why no data on the HAE attack rate in patients receiving the 75 mg dose of gene therapy? The results are only listed for the 25 mg dose. This is concerning.
  • P
    Crazy reaction to extraordinary news and presentation. I'll hold my shares and just see where this is in a couple of years.
  • S
    NTLA looks like it is about to drop. Be careful guys. I have been reading ( and their stocks have been doing way better.
  • J
    For HAE an attack rate reduction was listed for the 25 mg dose (91%) but no mention of the rate of HAE attack rate reduction at the 75 mg dose. This is very perplexing unless one assumes an unmentioned problem with the 75 mg dose. Either that or the rate reduction at the 25 mg dose was greater than the rate reduction at the 75 mg dose which throws the entire study conclusion into question.